利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

47 条记录 (耗时 0.028 秒)

    Biologically active molecules, conjugates thereof, and therapeutic uses
    3.
    发明授权
    Biologically active molecules, conjugates thereof, and therapeutic uses 有权

    公开(公告)号：US11345715B2

    公开(公告)日：2022-05-31

    申请号：US16740312

    申请日：2020-01-10

    申请人： REGENERON PHARMACEUTICALS, INC.

    发明人： Thomas Nittoli

    IPC分类号： C07D507/00 ,  A61K47/68 ,  A61K31/5365

    摘要： The present disclosure relates to linker compounds that are useful in covalently linking biologically active molecules with Ligands. The disclosed compounds also relate to biologically active molecules and Ligand conjugates, wherein the biologically active molecule is linked to the Ligand through a linker. The disclosure further provides compositions comprising biologically active molecule-ligand conjugates, methods of modifying abnormal cell growth and methods of treatment using the conjugates or the compositions.

    Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereof
    9.
    发明授权
    Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereof 有权

    公开(公告)号：US11485793B2

    公开(公告)日：2022-11-01

    申请号：US16913154

    申请日：2020-06-26

    申请人： Regeneron Pharmaceuticals, Inc.

    发明人： Lauric Haber ,  Eric Smith ,  Marcus Kelly ,  Jessica R. Kirshner ,  Sandra Coetzee ,  Alison Crawford ,  Thomas Nittoli ,  Yashu Liu

    IPC分类号： C07K16/30 ,  C07K16/46 ,  A61K39/395 ,  C07K16/28 ,  C07K16/44 ,  A61K47/68 ,  G01N33/574 ,  A61K39/00

    摘要： Mucin 16 (MUC16) is highly expressed in ovarian cancer and expression on cancer cells is shown to protect tumor cells from the immune system. The present invention provides novel full-length human IgG antibodies that bind to human and MUC16 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both MUC16 and CD3 and activate T cells via the CD3 complex in the presence of MUC16-expressing tumors. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human and monkey CD3, and a second antigen-binding molecule that specifically binds human and monkey MUC16. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing MUC16. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced MUC16-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including ovarian cancer. The present invention also includes anti-MUC16 antibody drug conjugates which inhibit tumor growth in vivo. In some embodiments, the anti-MUC16 antibodies are useful in diagnostic methods for identifying the presence of MUC16 in tissue and/or plasma samples.